Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Commission (EC) has allowed Astellas Pharma and Theravance to market Vibativ (telavancin hydrochloride) to treat adult patients with nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by MRSA when other alternatives are not suitable.
Subscribe to our email newsletter
Vibativ is an once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
Astellas Pharma Europe president and CEO Ken Jones said the approval of Vibativ can provide European healthcare professionals with a new, effective hospital antibiotic option for patients with hospital-acquired pneumonia caused by MRSA.